tiprankstipranks
Advertisement
Advertisement

CLLS Stock Latest News

Cellectis Showcases Safer Epigenetic Gene-Silencing Platform Ahead of ASGCT 2026
Company AnnouncementsCellectis Showcases Safer Epigenetic Gene-Silencing Platform Ahead of ASGCT 2026
2d ago
6K
CLLS
Cellectis Highlights Positive Pivotal Interim Data for Allogeneic CAR-T Partnered Cema-cel
PremiumCompany Announcements
Cellectis Highlights Positive Pivotal Interim Data for Allogeneic CAR-T Partnered Cema-cel
16d ago
6K
CLLS
Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments
PremiumThe Fly
Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments
16d ago
ALLO
CLLS
Cellectis Posts 2025 Results, Highlights Strong Allogeneic CAR-T Data and Cash Runway Into 2027
PremiumCompany Announcements
Cellectis Posts 2025 Results, Highlights Strong Allogeneic CAR-T Data and Cash Runway Into 2027
1M ago
6K
CLLS
Cellectis S.A. Sets March 19 Release Date for Q4 and Full-Year 2025 Results
PremiumCompany Announcements
Cellectis S.A. Sets March 19 Release Date for Q4 and Full-Year 2025 Results
2M ago
6K
CLLS
CLLS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsCLLS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
CLLS
Cellectis Sets 2026 Clinical Milestones and Extends Cash Runway Into H2 2027
Premium
Company Announcements
Cellectis Sets 2026 Clinical Milestones and Extends Cash Runway Into H2 2027
4M ago
6K
CLLS
Cellectis initiated with a Buy at Clear Street
Premium
The Fly
Cellectis initiated with a Buy at Clear Street
4M ago
CLLS
Cellectis Announces Arbitral Decision in Servier Dispute
PremiumCompany Announcements
Cellectis Announces Arbitral Decision in Servier Dispute
4M ago
6K
CLLS
Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
PremiumThe Fly
Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
4M ago
ALLO
CLLS
Cellectis announces arbitral decision in dispute with Servier
PremiumThe Fly
Cellectis announces arbitral decision in dispute with Servier
4M ago
CLLS
Cellectis Unveils Promising Phase 1 Results for Eti-cel at ASH 2025
PremiumCompany Announcements
Cellectis Unveils Promising Phase 1 Results for Eti-cel at ASH 2025
5M ago
6K
CLLS
Cellectis S.A. Updates Patent License Agreement with University of Minnesota
PremiumCompany AnnouncementsCellectis S.A. Updates Patent License Agreement with University of Minnesota
5M ago
6K
CLLS
Cellectis Unveils Breakthrough in Non-Viral Gene Editing with CssDNA
Premium
Company Announcements
Cellectis Unveils Breakthrough in Non-Viral Gene Editing with CssDNA
5M ago
6K
CLLS
Cautious Hold Rating for Cellectis SA Amid Key Clinical and Financial Milestones
Premium
Ratings
Cautious Hold Rating for Cellectis SA Amid Key Clinical and Financial Milestones
6M ago
CLLS
Cellectis S.A. Releases Interim Financial Report for Nine-Month Period Ending September 2025
PremiumCompany Announcements
Cellectis S.A. Releases Interim Financial Report for Nine-Month Period Ending September 2025
6M ago
6K
CLLS
Cellectis reports Q3 adjusted EPS 2c vs (22c) last year
PremiumThe Fly
Cellectis reports Q3 adjusted EPS 2c vs (22c) last year
6M ago
CLLS
CLLS Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CLLS Earnings this Week: How Will it Perform?
6M ago
CLLS
Cellectis Showcases Promising Clinical Trial Data at ASH 2025
PremiumCompany Announcements
Cellectis Showcases Promising Clinical Trial Data at ASH 2025
6M ago
6K
CLLS
Cellectis to present development update for eti-cel at ASH 2025
PremiumThe FlyCellectis to present development update for eti-cel at ASH 2025
6M ago
CLLS
Cellectis to Announce Q3 2025 Financial Results on November 7
Premium
Company Announcements
Cellectis to Announce Q3 2025 Financial Results on November 7
6M ago
6K
CLLS
Cellectis price target raised to $4 from $3 at Wells Fargo
Premium
The Fly
Cellectis price target raised to $4 from $3 at Wells Fargo
6M ago
CLLS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >